Background Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke. However, the risk of major stroke is very high for only the fi rst few days after TIA and minor ischaemic stroke, and observational studies show substantially greater benefi ts of early medical treatment in the acute phase than do longer-term trials. We hypothesised that the short-term benefi ts of early aspirin have been underestimated.
Introduction
The risk of recurrent stroke is up to 10% in the week after a transient ischaemic attack (TIA) or minor stroke. [1] [2] [3] [4] Urgent medical treatment seems to reduce that risk by as much as 80%, 5, 6 but many patients delay seeking medical attention, often for several days or weeks, even when they make a correct self-diagnosis.
have decreased delays to presentation after major stroke, 9, 10 but there has been little improvement in presentation rates after TIA or minor stroke (appendix p 1). 11 In a recent population-based study in the UK, half of recurrent strokes in the days after a TIA occurred prior to medical attention being sought for the initial event, 11 and the situation is likely to be worse in many parts of the developing world in which access to emergency services is poor.
Antithrombotic treatment is important in the immediate management of most acute ischaemic vascular events. 12, 13 Since aspirin is available in many house holds, public education materials recommend self-administration by patients who develop acute chest pain, in addition to seeking immediate medical attention. 14, 15 Prehospital self-administration of aspirin is discouraged after stroke 15 because of concerns about possible intracerebral haemorrhage. However, haemor rhage is a rare cause of TIA symptoms and it accounts for less than 5% of minor strokes. 16, 17 Although public education should continue to persuade people with transient neuro logical symptoms to seek medical attention immediately, where this is possible, self-administration of aspirin after tran sient unfamiliar symptoms might also be appropriate, particularly in rural settings or in less developed countries where access to medical services will be delayed.
There are, however, few published data from randomised trials for the eff ect of aspirin on risk of early recurrent stroke after TIA and minor stroke, and no data for its eff ect on severity; evidence of apparently major benefi ts of urgent medical treatment generally comes only from observational studies. 5, 18 Randomised trials of aspirin versus placebo in longer-term secondary prevention showed only a 13% relative reduction in risk of recurrent stroke with aspirin. 12, 13, 19 Trials of short-term treatment of hospitalised acute stroke also reported a 13% reduction in the 4 week risk of recurrent stroke or intracerebral haemorrhage, but the eff ect of aspirin on risk or severity of recurrence after more minor stroke was not reported. [20] [21] [22] Yet, observational studies suggest potentially substantial early benefi ts of aspirin after TIA or minor stroke. In the EXPRESS study, urgent treatment with antiplatelet drugs, blood pressurelowering drugs, and statins reduced the early risk of stroke by 80%; 5, 6 much of this decrease was hypothesised to have been due to aspirin. 5 Severity of recurrent cerebral events was also reduced in EXPRESS (appendix p 2), which might also have been due to aspirin.
In the absence of published randomised evidence of the eff ect of aspirin on risk and severity of early recurrent stroke after TIA and minor stroke, we reanalysed individual patient data and reviewed original paper records on early outcomes from all available trials of aspirin versus placebo in secondary prevention after TIA or ischaemic stroke. To inform on possible mechanisms of action, we also aimed to study the time course of the interaction between eff ects of aspirin and dipyridamole in secondary prevention of stroke. Aiming to more reliably estimate the very early time course of onset of eff ects of aspirin, we also studied risk of recurrent ischaemic stroke in trials of aspirin in treatment of acute stroke, stratifi ed by severity of the prerandomisation neurological defi cit.
Methods

Data selection and extraction
Trials were eligible if they randomised the following: patients with TIA or ischaemic stroke to regular aspirin (any dose; in the presence or absence of another
Research in context
Evidence before this study Previous systematic reviews of randomised trials of aspirin versus placebo in secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke reported only a 13% relative reduction in risk of recurrent stroke. Systematic reviews of trials of aspirin in treatment of hospitalised patients with acute stroke also reported a 13% reduction in the short-term risk of recurrent stroke or intracerebral haemorrhage. Yet, observational studies have suggested much more substantial benefi ts of urgent medical treatment after TIA or minor stroke, with the early risk of recurrent stroke reduced by as much as 80%, and a possible reduction in severity of stroke. The time course of benefi t of aspirin had not been studied in randomised trials or in any subsequent systematic reviews. Therefore, we did a pooled analysis of individual patient data from all available trials of aspirin versus control after TIA or ischaemic stroke.
Added value of this study
Our analyses of data from trials of aspirin in secondary prevention after TIA and ischaemic stroke show that the eff ect of aspirin on risk of early recurrent events has been underestimated. We show substantial reductions in the early risk of all stroke, ischaemic stroke, and acute myocardial infarction. We also found that a major part of the early benefi t of aspirin was due to a previously unrecognised reduction in severity of early recurrent ischaemic stroke, resulting in 80-90% reductions in the early risk of disabling or fatal recurrent ischaemic stroke after TIA and minor stroke. Although these trials recruited few patients in fi rst few days after TIA or stroke, we found similar reductions in risk of recurrent ischaemic stroke with aspirin in trials of acute ischaemic stroke.
Interpretation of all available evidence
Urgent medical treatment substantially reduces the risk of early recurrent stroke after TIA and minor stroke and early use of aspirin is the key intervention. Medical services should give aspirin as soon as possible and public education should be aimed at self-administration after unfamiliar transient neurological symptoms suggestive of threatened stroke.
See Online for appendix antiplatelet drug) versus no antiplatelet or anticoagulant in the secondary prevention of stroke and other vascular events; patients with acute ischaemic stroke to regular aspirin (any dose) versus no aspirin, in the presence or absence of another antithrombotic treatment, for acute treatment and prevention of early recurrence; or patients with TIA or ischaemic stroke to regular dipyridamole (any dose) versus no dipyridamole (in the presence or absence of another antiplatelet drug) in the secondary prevention of stroke and other vascular events. With searches done up to Jan 31, 2016, PMR identifi ed trials through searches of the Antithrombotic Trialists' (ATT) Collaboration, 13, 23 subsequent systematic reviews, and the Cochrane Collaboration. 24, 25 In view of the historical nature of the trials, no additional searches were made for ongoing trials or abstracts presented at meetings.
For all eligible trials of aspirin or dipyridamole in secondary prevention after TIA or stroke, we sought to obtain individual patient data. If these were not available, published data on vascular events were extracted from trial reports. Data were obtained on the following baseline variables: randomised treatment allocation, age, sex, prior diabetes, current smoking, history of hyper tension, blood pressure at entry, time from most recent cerebrovascular event to randomisation, nature of the most recent cerebrovascular event prior to randomisation (TIA; "minor" or non-disabling stroke; "major" or disabling stroke), and premorbid disability (modifi ed Rankin Scale [mRS] score). Data were also obtained on the nature and timing of the following outcome variables: any recurrent stroke, recurrent ischaemic stroke, acute myocardial infarction, intra cerebral haemorrhage, fatal extracranial bleeding, and cause of any other deaths. If available, from either electronic or paper records, data were obtained on the severity and outcome of all recurrent strokes (mRS score). There were minor diff erences in defi nition of recurrent stroke between trials, but designations made in the original trials were not changed.
For trials of aspirin in treatment of major acute stroke, we also sought to obtain individual patient data on the severity of stroke at entry (eg, a severity score or other measure of the extent on the baseline neurological defi cit) and on time to fi rst recurrent ischaemic stroke during the trial period. In one small trial, 26 only data for progression of stroke were collected (defi ned as a worsening of at least 2 points on the Scandanavian Stroke Progression Scale 27 ). In the absence of any other data, this outcome was included for completeness.
Statistical analysis
All analyses were by intention to treat based on the randomised treatment allocation. In the secondary prevention trials, we calculated the eff ects of aspirin versus control and dipyridamole versus control, with stratifi cation by time from randomisation (0-6 weeks, 6-12 weeks, and >12 weeks), for the following outcomes: recurrent ischaemic stroke, disabling or fatal recurrent ischaemic stroke, any recurrent stroke, any fatal stroke, intracerebral haemorrhage, and acute myocardial infarction. For each outcome, we calculated odds ratios (OR) for each trial and pooled estimates by fi xed-eff ects meta-analysis (Mantel-Haenszel-Peto method) if there was no signifi cant heterogeneity (χ² test) between trials. In the absence of signifi cant heterogeneity, we pooled individual patient data and generated Kaplan-Meier curves (1-proportion free of event) for time to fi rst event. Statistical signifi cance of any eff ect of randomised treatment allocation was determined using the log-rank test stratifi ed by trial and hazard ratios (HRs) and 95% CIs were generated for events up to 12 weeks follow-up using Cox proportional hazards models stratifi ed by trial (the assumption of proportional hazards was violated if events after 12 weeks were included). We compared the severity of early recurrent strokes between treatment groups based on mRS scores with ordinal regression (mRS shift) analysis. The assumption of proportional odds was assessed with the score test and was valid (p>0·3) for all analyses. However, we also calculated ORs for the traditional single cutoff point of an mRS score of higher than 2. Stratifi ed analyses of the preventive eff ect of treatment on recurrent ischaemic stroke and on disabling or fatal recurrent ischaemic stroke were also done for the following potential eff ect modifi ers: dose of aspirin (<100 mg [low] vs ≥300 mg [high]), TIA or minor stroke only versus major stroke (usually defi ned as the presence of residual neurological signs) at baseline; time from last TIA or minor stroke to randomisation (≤14 days vs >14 days), age (<65 years vs 65-74 years vs ≥75 years), sex, diabetes, current smoking, and hypertension (prior diagnosis or blood pressure ≥160/90 mm Hg at baseline assessment vs none).
In trials of aspirin for acute stroke, we determined the eff ect of aspirin versus control on risk of recurrent ischaemic stroke. Trials diff ered in duration of randomised treatment allocation (appendix p 3). To maximise comparativeness between the trials, we fi rst determined the eff ect of aspirin up to day 14 after randomisation, stratifi ed by the severity of the stroke at the baseline assessment. In the two largest trials, data for the extent of baseline neurological defi cit had been collected in the same way, with documentation of the presence or absence of neurological defi cits of the following types: face, arm or hand, leg or foot, dysphasia, visuospatial, brainstem or cerebellar, hemianopia, and other. We quantifi ed the severity of stroke as follows: mild (≤2 defi cits), moderately severe (3-4 defi cits), and severe (≥5 defi cits). A third smaller trial had quantifi ed baseline severity of stroke using approximate quartile categories of the Scandinavian Stroke Progression Scale 27 score (<9, 10-11, 12-13, and 14-25). The distribution of severity that most closely matched that in the other two trials was: mild (<9), moderately severe (10-14), or severe (14-25).
We calculated ORs for the eff ect of aspirin on the 14 day risk of recurrent ischaemic stroke for each trial, with stratifi cation by severity of initial stroke. Pooled estimates were obtained by fi xed-eff ects meta-analysis (Mantel-Haenszel-Peto method) if there was no signifi cant heterogeneity (p>0·05 on χ² test) between trials, or otherwise by random-eff ects meta-analysis. To determine the time course of onset of eff ect of aspirin in the acute phase, we did a pooled analysis, stratifi ed by time from randomisation to recurrent ischaemic stroke (days 0-1, 2-3, 4-6, 7-14, and ≥15). This analysis covered the full period of randomised treatment allocation in the trials and was done both with and without the patients in the International Stroke Trial (IST) 20 who had been taking aspirin prior to randomisation. Prior aspirin use was an exclusion criterion in the smaller trial 26 and was rare in the Chinese Acute Stroke Trial (CAST).
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The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
We identifi ed 12 trials of 15 778 participants that assessed aspirin versus control in secondary prevention after TIA or ischaemic stroke (appendix p 3). Data for recurrent vascular events within 12 weeks of randomisation were available for all these trials. 11 trials included com parisons of aspirin alone versus placebo, and three trials included comparisons of aspirin plus dipyridamole versus no aspirin.
Among 9635 participants in the 11 trials of aspirin only versus control, aspirin reduced the 6 week risk of recurrent ischaemic stroke by about 60% (HR 0·41, 95% CI 0·30-0·56; p<0·0001; table 1), with a similar eff ect at 12 weeks (table 1) and no heterogeneity between trials (p het =0·85; appendix p 5). Inclusion of data from the three additional trials for comparisons for aspirin plus dipyridamole versus no aspirin (ie, any aspirin) did not change the result (HR 0·42, 95% CI 0·32-0·55, p<0·0001; table 1). Benefi t was greatest at 0-2 weeks (fi gure 1), but further benefi t accrued up to 12 weeks follow-up (table 1, fi gures 1, 2).
Aspirin also reduced the severity of recurrent ischaemic stroke during the 6 weeks after randomisation (fi gure 3), with a similar eff ect seen at 12 weeks and when analyses were based only on an mRS score higher than 2 (fi gure 3). Consequently, aspirin reduced the 6 week risk of disabling or fatal (mRS score >2) ischaemic stroke by about 70% (table 1; p het =0·91) and the risk of very severe (mRs score 4-6) ischaemic stroke by about 75% (26 of 8452 participants in active group had an event vs 92 of 7326 in control group; HR 0·25, 0·16-0·39, p<0·0001), but had less eff ect on non-disabling (mRs ≤2) stroke (48 of 8452 participants had an event vs 65 of 7326; HR 0·64, 0·44-0·93, p=0·020). Benefi t continued to accrue for risk of disabling or fatal ischaemic stroke up to 12 weeks follow-up (table 1, fi gures 1, 2), but the greatest reduction was seen within the fi rst 2 weeks, particularly in patients presenting with TIA and minor stroke (two of 6691 participants in the aspirin group with TIA or minor stroke had a disabling or fatal ischaemic stroke vs 23 of 5726 in the control group, 95% CI HR 0·07, 0·02-0·31, p=0·0004; fi gure 1). Aspirin also reduced the early risks of any recurrent stroke, fatal stroke, and acute myocardial infarction (table 1) . There was no increase in the 12 week risk of intracerebral haemorrhage on low-dose aspirin versus control (three of 4125 participants in active group had an event vs fi ve of 4137 in the control group), but there was a trend towards higher risk for high-dose aspirin compared with control (fi ve of 4297 vs one of 3159; HR 3·68, 95% CI 0·43-31·51, p=0·23). However, four of the events on high-dose aspirin occurred as complications of carotid endarterectomy in the UK-TIA Aspirin Trial (three in patients assigned to 1200 mg of aspirin and one to 300 mg). There was only one fatal extracranial bleed within 12 weeks of randomisation in any of the trials (on aspirin plus dipyridamole in the European Stroke Prevention Study [ESPS]-2).
The eff ect of aspirin on the 12 week risk of recurrent ischaemic stroke was independent of dose and patient characteristics (table 2, fi gure 1, appendix p 6). In trials where data were available (5606 assigned to aspirin vs 4803 to control), we found a similar eff ect on 12 week risk of disabling or fatal recurrent ischaemic stroke in patients with atrial fi brillation at baseline (HR 0·28, 95% CI 0·08-1·00, p=0·0508) and in those with lacunar stroke (data in ESPS-2 only; data not shown). There was also no interaction between time from the last TIA or stroke to randomisation and the eff ect of any aspirin versus control on the 12 week risks of ischaemic stroke or of disabling or fatal ischaemic stroke (table 2) . Aspirin reduced the 12 week risk of disabling or fatal ischaemic stroke in patients recruited fewer than 14 days after their last event (HR 0·46, 0·27-0·77, p=0·0035), but there were too few patients recruited within 7 days to defi ne the eff ect of treatment during this time.
The absolute risk of recurrent ischaemic stroke fell with time from randomisation (p interaction <0·0001; fi gure 2). In trials of aspirin only versus control, there was no reduction in risk of recurrent ischaemic stroke after 12 weeks (OR 0·97, 95% CI 0·84-1·12, p=0·67; p int <0·0001 for <12 weeks vs >12 weeks), with no heterogeneity between trials (appendix p 7). There was also no reduction in severity of post-12-week strokes (mRS shift OR 1·00, 95% CI 0·77-1·29, p=0·97).
We identifi ed eight trials (11 937 participants) of dipyridamole versus control (with or without aspirin) in secondary prevention after TIA or ischaemic stroke (appendix p 3). Three trials with comparisons of aspirin plus dipyidamole versus no antiplatelet were included in the any aspirin versus control analyses described above. Seven trials (9437 participants) included comparisons of dipyridamole plus aspirin versus aspirin alone, and one trial (6602 participants) also included com parisons of dipyridamole versus aspirin and dipyridamole versus control (appendix p 3). Data for recurrent vascular events within 12 weeks of randomisation were obtained for all of these trials. Adding dipyridamole to aspirin had no eff ect on the 12 week risk of recurrent ischaemic stroke (OR 0·90, 95% CI 0·65-1·25, p=0·53; appendix p 11), with no heterogeneity between trials (p het =0·31), and had no eff ect on severity of recurrent ischaemic stroke within 12 weeks of randomisation (mRS shift analysis OR 0·90, 95% CI 0·37-1·72, p=0·99). However, adding dipyridamole to aspirin did reduce the risk of recurrent ischaemic stroke after 12 weeks (OR 0·76, 95% CI 0·63-0·92, p=0·005), particularly the risks of disabling or fatal ischaemic stroke (0·64, 0·49-0·84, p=0·0010) and any disabling or fatal stroke (0·65, 0·51-0·84, p=0·0008). Dipyridamole versus control also had no eff ect on severity of 12 week recurrent ischaemic stroke in the ESPS-2 trial (mRS shift analysis for any dipyridamole vs control OR 0·98, 95% CI 0·58-1·66, p=0·95; dipyridamole only vs control OR 1·11, 0·59-2·09, p=0·74). Given the small numbers of patients randomised within 7 days of their last event in the trials of aspirin in secondary prevention after TIA or stroke, we studied the time course of risk of recurrent ischaemic stroke in trials of aspirin in treatment of acute stroke, in which all patients were randomised within 48 h of stroke onset. Among three eligible trials (40 531 participants, appendix p 8), individual patient data were available from the two largest (40 090 participants) and tabular data from the smaller trial (441 participants). The eff ect of aspirin versus control on the 14 day risk of recurrent ischaemic stroke diff ered in relation to the severity of stroke (p het =0·014), as indicated by the extent of the baseline neurological defi cit (appendix p 9). Aspirin reduced the 14 day risk of recurrent ischaemic stroke in participants with mild neurological defi cits at baseline, with a consistent eff ect across the trials, but had no eff ect in those with severe defi cits at baseline (appendix p 9). In participants with moderately severe defi cits, there was a signifi cant overall reduction in risk, but there was heterogeneity between trials (appendix p 9). There was no interaction (p=0·92) between the eff ect of aspirin on recurrent ischaemic stroke and randomisation between heparin and no heparin in the IST (data not shown). On pooled analysis of recurrent ischaemic stroke in patients with mild and moderately severe initial defi cits, no eff ect of aspirin was found within the fi rst 24 h (fi gure 4) after randomisation, but risk was reduced by day 2 (HR 0·44, 95% CI 0·25-0·76, p=0·0034) and day 3 (0·31, 0·16-0·58, p=0·0003), with further reductions during days 4-6 (0·45, 0·31-0·67, p<0·0001) and days 7-14 (0·64, 0·45-0·91, p=0·0121), but not after 14 days (0·86, 0·58-1·27, p=0·45; fi gure 4). Results were similar after inclusion of 3292 (21%) participants in IST who had received aspirin during the days before randomisation (fi gure 4, appendix p 10). Of note, allocation to continued aspirin in this group did reduce the risk of recurrent ischaemic stroke in the fi rst 24 h (HR 0·31, 95% CI 0·11-0·85, p=0·020).
Discussion
Our analyses of trials of aspirin in secondary prevention after TIA and ischaemic stroke show that the eff ect of aspirin on early recurrent events has been underestimated. We identifi ed substantial reductions in the early risks of all stroke, ischaemic stroke, and acute myocardial infarction with aspirin, with eff ect sizes greater than those previously reported after unstable angina or acute myocardial infarction. 23 We also found that a major part of the early benefi t of aspirin was due to an hitherto unrecognised reduction in severity of early recurrent ischaemic stroke, resulting in up to a 90% reduction in early risk of disabling or fatal recurrent ischaemic stroke after TIA and minor stroke.
However, trials of aspirin for secondary prevention recruited few patients in the acute phase after TIA or stroke. We found no signifi cant diminution of the eff ect in patients randomised early, but acute eff ects might diff er. For example, aspirin had no eff ect on death for the fi rst 3 days after acute myocardial infarction in the ISIS-2 trial. 28 We therefore studied trials of aspirin in treatment of acute stroke, aiming simply to estimate the time course of onset of eff ect of aspirin on risk of recurrent ischaemic stroke, with the overall balance of risk and benefi t having been documented elsewhere. [20] [21] [22] With use of stratifi cation by severity of the baseline neurological defi cit, we showed that in patients with less severe stroke the relative reduction in risk of recurrent ischaemic stroke on aspirin was similar to that in the secondary prevention trials and was evident by the second full day of treatment. Aspirin could also have reduced further thrombosis, or related processes, in patients with more major stroke, but such eff ects would probably be less clinically evident in the territory of an already large cerebral infarct.
Our results have implications for acute treatment after TIA and minor stroke. First, they confi rm fi ndings from previous non-randomised studies for the impact of urgent treatment on the early risk of recurrent stroke, 5, 6, 18 supporting recommendations for urgent assessment of patients. Second, they suggest that most of the benefi t of urgent treatment in these previous multi-intervention studies was simply due to aspirin. Therefore, it is essential that patients with TIA or minor stroke are not sent home from the emergency department with advice to add aspirin to their next prescription; they should be treated acutely. Similarly, patients who telephone their family doctor or advice lines should be told to take aspirin immediately if TIA is suspected, in addition to obtaining medical attention. Aspirin could also be given by paramedics when they assess patients at home. Third, we showed that aspirin reduced early recurrent stroke in non-anticoagulated patients with atrial fi brillation at baseline.
Our fi ndings also have implications for the choice of antithrombotic treatment early after TIA or ischaemic stroke. Most guidelines do not distinguish between the early and later phases of secondary prevention and several recommend clopidogrel monotherapy or other drugs as equal alternatives to aspirin. 29, 30 Our fi ndings suggest that treatment in the fi rst few days and weeks should include aspirin unless some other antithrombotic agent is shown to be superior. We found that dipyridamole monotherapy was inferior to aspirin in prevention of early recurrent stroke, and that addition of dipyridamole to aspirin did not enhance the eff ects of aspirin on risk or severity of early recurrent ischaemic stroke. Clopidogrel plus aspirin does appear to be more eff ective than aspirin alone in prevention of early recurrent stroke after TIA and minor ischaemic stroke, 31, 32 but has no eff ect on severity of stroke, 33 and the only trial of clopidogrel monotherapy versus aspirin plus dipyridamole in this patient group reported data that, in light of our fi ndings, suggest increased severity of early recurrent stroke in the clopidogrel group. 34 Indeed, although the PROFESS trial showed no diff erence in overall severity of recurrent stroke on aspirin plus dipyridamole versus clopidogrel in secondary prevention after TIA and ischaemic stroke, 35 our fi ndings suggest that risk and severity of early recurrent stroke might have been reduced by aspirin plus dipyridamole in patients who were randomised soon after their initial TIA or stroke, such that the early eff ects of aspirin would not already be lost after prolonged pre-randomisation use. Diminishing benefi t of aspirin with longer pre-randomisation use would also explain why the advantage of aspirin plus clopidogrel compared with clopidogrel alone in the MATCH trial was only seen in patients randomised early after their TIA or stroke, 36 and possibly why previous observational studies of severity of ischaemic stroke in relation to previous aspirin use have yielded confl icting results. Similar considerations will apply to trials of cilostazol, ticagrelor, and future novel anticoagulants in secondary prevention of stroke. In fact, survival curves in trials of aspirin versus cilostazol suggest that aspirin is superior for the fi rst 3 months, but cilostazol is more eff ective thereafter. 37, 38 Future trials of new antiplatelet or antithrombotic drugs in prevention of early recurrent stroke should report data for severity of stroke and should avoid mixing patients taking aspirin with those taking other antiplatelet drugs in the comparator arm.
Our fi ndings also have implications for public education. First, confi rmation that urgent treatment after TIA and minor ischaemic stroke reduces the early risk of disabling or fatal stroke by about 80% highlights the need to reduce delays in patients seeking medical attention. Second, since aspirin is available in many house holds, consideration should be given to promoting self-administration immediately after tran sient strokelike neurological symptoms, as is recom mended for people who have acute chest pain. 14, 15 Intracranial haemorrhage is rare in patients with TIA symptoms and accounts for less than 5% of minor strokes. 16, 17 Moreover, randomised trials of anti thrombotic drugs that have included patients with acute intracranial haemorrhage have not shown any increase in risk of death or of recurrent haemorrhage. 39 Similarly, there is no evidence that prior aspirin would worsen outcome in the small proportion of patients who still subsequently progressed to have a major stroke and required thrombolysis or thrombectomy. 40, 41 Indeed, given the substantial reductions in progression to disabling or fatal early recurrent ischaemic stroke that we noted with aspirin, prevention of the need for thrombolysis or thrombectomy will be the main benefi t. Public education should continue to persuade people with transient unfamiliar neurological symptoms to seek medical attention immediately, where this is possible, but self-administration of aspirin would also be prudent, particularly in rural settings or in less developed countries where access to emergency services might be delayed. Some individuals would take an aspirin or two unnecessarily, as is the case with noncardiac chest pain, but others would benefi t.
For longer-term secondary prevention after TIA and ischaemic stroke, aspirin had no signifi cant eff ect on risk or severity of recurrent ischaemic stroke after 12 weeks. However, early benefi t of aspirin was maintained on longer-term follow-up, even though no additional benefi t accrued. More detailed analyses of trials in a broader range of secondary prevention settings, and including all relevant outcomes, are underway to establish the longerterm balance of risk and benefi t (Rothwell PM, unpublished), and new trials should determine the risk and benefi ts of stopping aspirin. The absence of additional benefi t after 12 weeks does, however, necessitate re-interpretation of trials of long-term secondary prevention of stroke with other antithrombotic drugs versus aspirin that have shown either no benefi t of the other drug 42 or only a small benefi t. 43 The interpretation that these drugs are as eff ective as aspirin is less positive if aspirin is ineff ective.
We found no evidence that adding dipyridamole to aspirin reduced the risk or severity of early recurrent ischaemic stroke. However, dipyridamole plus aspirin versus aspirin alone did reduce the risk of later recurrent ischaemic stroke and this eff ect was particularly marked for disabling or fatal events. Further work is required to fully understand the nature of this late eff ect in the trials that we studied here and in the PROFESS trial. 35 Our results do have limitations. First, the trials of aspirin in secondary prevention were done in the 1980s and 1990s. Medical care has since changed, with more detailed investigations and more intensive lowering of blood pressure and lipids. However, the eff ect of urgent treatment after TIA and minor stroke that was observed in more recent observational studies 5, 6, 18 is very similar to that in the previous trials (appendix p 2). Changes in medical care would also impact less on the eff ectiveness of prehospital self-administration. Second, most patients in the secondary prevention trials were already beyond the very early high risk period after their initial TIA or minor stroke when recruited. 44 However, delayed inclusion is likely to have underestimated the absolute reduction in risk of early recurrent stroke, as might the absence of a loading dose in the trials of low-dose aspirin, but relative risk reductions are likely to be generalisable to the acute phase. The absolute reduction in risk of ischaemic stroke in the EXPRESS study in which patients were treated more acutely was about 8% (number needed to treat 12; appendix p 2). 5 We did not fi nd a reduction in recurrent ischaemic stroke during the fi rst 24 h in trials of aspirin in the acute treatment of major stroke (fi gure 4), but early deterioration after major stroke is multifactorial and recurrent stroke is diffi cult to distinguish from progression of existing pathological processes. There was no evidence of a delay in onset of benefi t of acute treatment after TIA and minor stroke in observational studies in the acute phase. 5, 6, 18 Third, some patients in the trials of aspirin in secondary prevention were treated with aspirin or other antithrombotic drugs for a short time after their initial TIA or stroke, prior to inclusion. However, we found no evidence that such treatment infl uenced the eff ect of subsequent randomised treatment, either in the SALT trial (appendix p 5), which had a short on-treatment run-in, or in the other secondary prevention trials (data not shown). However, prior aspirin use was associated with benefi t within the fi rst 24 h in the IST trial (appendix p 10). Finally, we did not report data on whether non-compliance with trial treatment might explain the diminishing longer-term benefi t of aspirin. However, preliminary analyses show little evidence of this (Rothwell PM, unpublished) and compliance was clearly suffi cient to show the late benefi ts of dipyridamole plus aspirin versus aspirin alone.
Our fi ndings raise questions about the mechanisms by which aspirin reduces the risk and severity of early recurrent ischaemic stroke and by which eff ectiveness diminishes with longer-term use. It is unusual for preventive treatments to reduce the risk of disabling stroke more than non-disabling stroke, which might suggest a neuroprotective eff ect of aspirin, possibly due to prostaglandin-mediated eff ects on the microvasculature. 45, 46 However, the similarly large reduction in the early risk of myocardial infarction suggests reversal of short-term systemic platelet activation. The loss of benefi t of aspirin in longer-term use is at odds with the maintenance of platelet COX-1 inhibition, 47 although time-course data on bleeding time are less clear-cut. 48 It is possible that aspirin is only clinically eff ective during periods when platelets are activated, or that platelets adapt to aspirin via upregulation of non-COX-mediated pathways, or that gradual acetylation of other proteins aff ects other important pathways. 49 In conclusion, we show the validity of previous nonrandomised studies that reported the considerable impact that medical treatment has on the early risk of recurrent stroke after TIA and minor ischaemic stroke and we have identifi ed aspirin as the key component. It is essential that aspirin is given to patients with suspected TIA or minor stroke immediately. Indeed, a case can be made for public education about self-administration after transient unfamiliar neurological symptoms. The previously unrecognised reduction in severity of early recurrent ischaemic stroke by aspirin has important implications for clinical guidelines, interpretation of previous and future trials, and for understanding mechanism of action. More generally, our fi ndings highlight the fact that to understand the eff ects of newer drugs in comparison to, or in combination with, older drugs, it is fi rst necessary to fully understand the eff ects of the older drug.
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